CAG
REGN icon

Csenge Advisory Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Csenge Advisory Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-387
Closed -$276K – 733
2024
Q4 		$276K Sell
387
-76
-16% -$63.8K 0.02% 568
2024
Q3 		$470K Buy
463
+41
+10% +$45.6K 0.02% 435
2024
Q2 		$444K Sell
422
-27
-6% -$26.2K 0.03% 432
2024
Q1 		$432K Buy
449
+49
+12% +$46.6K 0.02% 467
2023
Q4 		$351K Buy
400
+107
+37% +$88.1K 0.02% 488
2023
Q3 		$241K Buy
+293
New +$230K 0.02% 540
2023
Q2 		– Sell
-264
Closed -$217K – 691
2023
Q1 		$217K Sell
264
-14
-5% -$10.6K 0.02% 539
2022
Q4 		$201K Buy
+278
New +$205K 0.02% 561
2022
Q2 		– Sell
-302
Closed -$211K – 654
2022
Q1 		$211K Buy
+302
New +$191K 0.02% 593
2021
Q1 		– Sell
-417
Closed -$201K – 517
2020
Q4 		$201K Sell
417
-774
-65% -$418K 0.02% 411
2020
Q3 		$693K Buy
1,191
+3
+0.3% +$1.82K 0.1% 172
2020
Q2 		$741K Buy
1,188
+546
+85% +$310K 0.11% 144
2020
Q1 		$313K Buy
+642
New +$265K 0.08% 207
2018
Q4 		– Sell
-3
Closed -$1K – 1183
2018
Q3 		$1K Buy
+3
New +$1.14K ﹤0.01% 911

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Csenge Advisory Group's REGN Position: Q1 2025 in Review

Csenge Advisory Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 387 shares — an estimated $276K sold.

Csenge Advisory Group first reported a position in REGN in Q3 2018 and held it in 14 quarters. The position peaked at $741K in Q2 2020. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Csenge Advisory Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Csenge Advisory Group sold 387 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $276K.
  • Csenge Advisory Group first reported a position in Regeneron Pharmaceuticals in Q3 2018 and held it in 14 quarters.
  • Csenge Advisory Group's Regeneron Pharmaceuticals position peaked at $741K in Q2 2020.
  • 1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Csenge Advisory Group's 13F filing for Q1 2025, filed 5 May 2025.